Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP001342

Drug Information
NameAclarubicin
SynonymsMolPort-004-845-383; AC1L27WP; LS-93909; NSC 208734; KBio2_003515; CID152688; Aclarubicin (USAN/INN); KBio2_006083; AC1L48VL; Aclacin; CID154943; SMP1_000003; Antibiotic MA 144A1; Aclarubicino [INN-Spanish]; BCBcMAP01_000191; CID6712061; MolPort-003-665-565; MolPort-003-983-841; 64520-15-6; NSC240619; 10-epi-Aclacinomycin A; NINDS_000678; acene-1-carboxylate; QTL1_000003; CID451415; 72711-48-9; 79617-46-2; KBio1_000678; NCIMech_000395; Spectrum_000467; HMS502B20; C42H53NO15; AC1L4DB3; CHEMBL45414; CHEBI:170281; DivK1c_000678; .alpha.-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; Aclarubicino; Neuro_000108; AC1O8MK9; NSC-208734; Antibiotic MA144-A1; KBioGR_001156; Spectrum2_001934; AC1L9PMJ; Spectrum4_000768; Aclarubicin [USAN:BAN:INN]; STK177207; MA 144G1; IDI1_000678; LS-93950; MA 144-A1; D02756; LS-93943; A8959_SIGMA; NSC208734; Aclarubicine [INN-French]; Aclarubicine; AC1L1CQ0; Antibiotic MA 144G1; Spectrum5_001041; KBioSS_000947; NCI60_001746; CCRIS 2262; 57576-44-0; NCI60_018879; AC1O8OA8; aclarubicin; CID6713097; Aclacur; Jaclacin; UNII-74KXF8I502; SPBio_001967; AC1L7CAE; EINECS 260-824-3; CID42474; KBio2_000947; Aclacinomycin A; CID2008; HMS2089B13; 77448-81-8; CID308141; Aclucinomycin A; MA-144A1; NSC-208,734; Antibiotic MA 144A; CHEMBL502620; Aclarubicinum; Aclarubicinum [INN-Latin]
IndicationCancer
[ICD9: 140-229   ICD10: C00-C96]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38
(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)3
9(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)
53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17
H2,1-7H3/t18-,19+,20+,24+,27+,28+,29+,30+,31+,35+,39-,40-,42-/m1/
s1
InChIKeyUSZYSDMBJDPRIF-IFRWQTOUSA-N
Canonical SMILESCCC1(CC(C2=C(C1C(=O)OC)C=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4O)OC5CC(C(C(O5)
C)OC6CC(C(C(O6)C)OC7CCC(=O)C(O7)C)O)N(C)C)O    
Isomeric SMILESCC[C@]1(C[C@@H](C2=C([C@H]1C(=O)OC)C=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4O)O
[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@
H]7CCC(=O)[C@H](O7)C)O)N(C)C)O
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 57576-44-0
FormulaC42H53NO15
PubChem Compound IDCID 152688.
PubChem Substance IDSID 730204.
SuperDrug ATC IDL01DB04
SuperDrug CAS ID057576440;
TargetDNA topoisomerase IIInhibitor[2][3]
Ref 1Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. To Reference
Ref 2Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines. Anticancer Drug Des. 2001 Dec;16(6):305-15. To Reference
Ref 31,3-Dihydroxyacridone derivatives as inhibitors of herpes virus replication. Antiviral Res. 2000 Feb;45(2):123-34. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543